According to the observations in NfL levels, mean concentrations after 2 months of treatment in SMA type 1 patients were lowered to those at baseline in SMA type 2 and 3 patients (Table 4; Figure 3). The gene discussed is NEFL; the disease is spinal muscular atrophy, type 1.